Oramed Pharma Receives $18M Payment From Scilex Holdings, Representing $118M Total Returns On $99.5M Investment; Oramed Retains $39M Outstanding debt, Convertible Debt, Warrants, and Ongoing Royalty Interest

Benzinga · 3d ago

Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest

NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties.